COVID-19 Impact on Diabetes Management (iNPHORM, USA)

This American study quantifies how and the extent to which glycemic management has suffered due to COVID-19, nearly one year after the first USA-based case was detected. This cross-sectional study evaluates a real-world cohort of Americans (≥18 years old) with type 1 or type 2 diabetes (T1D, T2D) taking insulin and/or secretagogues (iNPHORM study, January 2021). A sample of 772 respondents was analyzed (T1D: 18.9%; male: 49.5%; age: 52.1 [SD:...